Now live: Pro — the full 13F research suite for serious investorsSee pricing →
JOHNSON & JOHNSON (JNJ)

Q3 2024 · 13F-HR

JOHNSON & JOHNSON (JNJ)holdings as filed

Filed 2024-11-13 · accession 0000904454-24-000604

$427.3M
Reported value
20
Positions
2024-09-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
74366E102PTGXProtagonist Therapeutics Inc.$110.2M25.8%2,449,183CommonSHARED
75383L102RAPPRapport Therapeutics, Inc.$51.2M12.0%2,498,051CommonSHARED
52490G102LEGNLegend Biotech Corporation$39.7M9.29%814,586CommonSHARED
21217B100CTNMContineum Therapeutics Inc.$37.9M8.86%1,979,173CommonSHARED
126638105CVRXCVRx, Inc.$36.2M8.46%4,103,430CommonSHARED
63009J107NBTXNanobiotix S.A.$32.3M7.57%5,623,816CommonSHARED
74276L105PRCTProcept BioRobotics Corporation$28.7M6.71%357,939CommonSHARED
G59665102MGTXMeiraGTx Holdings plc$27.7M6.48%6,641,064CommonSHARED
640979100NMRANeumora Therapeutics, Inc.$24.4M5.72%1,849,445CommonSHARED
98401F105XNCRXencor, Inc.$15.0M3.52%748,062CommonSHARED
31189P102FATEFate Therapeutics, Inc.$11.8M2.77%3,379,064CommonSHARED
04280A100ARWRArrowhead Pharmaceuticals, Inc.$4.8M1.12%247,598CommonSHARED
75120L100Rallybio Corporation$4.3M1.00%3,636,363CommonSHARED
M70700105NNOXNano-X Imaging Ltd.$965,8200.23%158,852CommonSHARED
929033108Vor Biopharma, Inc.$752,2610.18%1,074,658CommonSHARED
34385P108LABStandard BioTools Inc$602,0960.14%311,967CommonSHARED
007002108TORCEURAdicet Bio, Inc.$524,8400.12%364,472CommonSHARED
09090D103BiomX Inc.$196,1670.05%192,321CommonSHARED
185063104CLSDUSDClearside Biomedical, Inc.$104,7510.02%82,481CommonSHARED
81727U105SENS1GBPSenseonics Holdings, Inc.$19,1010.00%54,621CommonSHARED

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.